Biosimilars Market Access in Psoriasis

Biosimilars Market Access in Psoriasis

  • March 2017 •
  • 24 pages •
  • Report ID: 4883994 •
  • Format: PDF
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.
Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors.

This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.